Oragenics (NYSE:OGEN) Research Coverage Started at StockNews.com

StockNews.com initiated coverage on shares of Oragenics (NYSE:OGEN) in a research note released on Sunday. The brokerage issued a sell rating on the stock.

Oragenics Stock Up 3.4 %

Oragenics stock opened at $0.38 on Friday. The firm has a market capitalization of $4.62 million, a P/E ratio of -0.05 and a beta of 0.43. The firm has a fifty day moving average of $0.33 and a 200-day moving average of $0.74. Oragenics has a 52-week low of $0.25 and a 52-week high of $7.74.

About Oragenics

Oragenics, Inc, a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus.